Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for mirikizumab

  1. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

  2. Mirikizumab for treating moderately to severely active Crohn's disease ID6244

    In development [GID-TA11267] Expected publication date: TBC

  3. Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209

    In development [GID-TA11184] Expected publication date: TBC